Page 48 - Demo

Once a day is the way1 Adherence is key to success with PrEP.2 Encourage patients to take their tablet at the same time each day.1 cy The PBS allows two repeats on a PrEP prescription.3 Mylan is the Australian PrEP market leader – 41% of all PrEP units sold in Australia are Mylan products.4 TO ORDER MYLAN SPEAK WITH YOUR MYLAN BUSINESS COACH TODAY R R R G .A t G Gu h .M h h A A A A A L L L e e ef u u t t tt u u u u u G G G t f f i i i tp p p s s s s s B B B e e er d d d t t t t e e : : :/ tr r r r r T T r r el / / TQ l a a a a a Q Q e e e li / / / i i l l l l l n n n n n ne w w w i i i i e e ia = = = a a a a l l c c c w w w le s s ) ) ) ) e e e sU w w w. )A e es s s A A A A s s s U U . .p b b b : : : 1 p p p p p B B B B B i i ia b b N N N N N 9 a an 1 1 d d da bs n s s n, , . . . . 2 a at . . t t .g g 9 9 9 9 ,g T y /200 C y of HI T Te e e e go o 3 3 3 3 e e . . ov 30 g g a a ay v v n n no .P 0 0 0 P . . .a 00 y y , , , b o o Pr a a 0 0 0 0 r f f fo re e u u u/ 2 2 2 2 o o ev 23 b b i i i v v / / s s s v v v 3 3 3 3 e e e m m e e e i i me 5 5 5 5 5 x x rD M . Th ir r D n n n e 9 9 9 9 t t t H ed d d D 97 xu u ua i i i a a 7 7 7 i i i H H c c ci 73 l l l, BECAUSE EVERY COMMUNITY IS A DIVERSE ONE s s s I I I i in 3 3 3 3 , n n ,t 9 9 9 9 9 t t Men in your community are being prescribed PrEP (pre-exposure prophylaxis) to help reduce their risk of contracting HIV. o o o V V V b p p p e e e . . . . . L r r r a a a r r ro b b / / /i i i L L L L o o n n n y y e e e e x x xi yP t t te e e ev s s s v v v i i P ve g g l l lE Pr m m e e e r r m/ el ge e e l l l l 1 E E e e e / /1 n n n m m m s s sc 1 1 1 1 1 1 d d d , , , , , 3 du c c 1 1 1 e e e t t tr r r r 1 1 1 r r r r ri i i 3 3 3 i i ib 4 4 4 b b 30 , , , q u c c c 9 9 9 0 0 0 0 q q i i i i i it n n - - - - - u u t t ng T T T - - - 3 3 3 3 3 ue e e c c t a a ab g g P 1 1 11 4 4 4 4 4 H b b 1 e e e r r i i P P 12 2 2 ti in n n r r r H H H 9 9 9 Hi r. . . i i i i e e E E EP 6 6 c c c c P P. 6M ck k k k k i eM l M . s s s s s n n f .S M M . . y y S Sy .A o o o o o l la y y A Ac n n n n n R fo a a d d n n dn c c n n c c c R R R or n3 Ro e e o o o o 3 3 ey e e e y y, s s s a a a a a rm 0 0 00 , , 2 s s s d d d d d 0 0 2 2 e e e , , , , , M / / C 0 0 019 d d d 6 M M Mi 9 i i il l ll . 3 P . Au Ma l le e e 3. ay r r r o s s s P n y2 P P s su u 20 u o o o oi i i m me st 02 20 in n nt r t t e ra 0. My . 4 : t N r r M l lia 4. N N NS M a S S n e ed nG W W di W2 ic 2 2 c Gove yl la a 0 0 0 in n er n D 0 0 0 00 e I r 0 0. . . T In nm Da at nform ta T Te en a o e e e l l l nt : : : t D :1 mat n n F 1 Dep 18 F 8 8 8 i il 0 0 0 i io 0 0 0 on part le eM 0 2 2 2 . h t Ma 7 7 7 2 m ay 4 4 4 en y2 42 2 2 When dispensing PrEP nt 20 7 7 7 to 02 6 6 6. . . e A of 0 f H . w w ww i y: : Your Mylan Business Coach can answer questions you have about PrEP and provide support materials to help you interact with your local LGBTQ community. in Aust H 0. Co w w w e n y ea op w w w w. tra a . . lt pyri th m m m my la h. y y yo a l l s .P ig g la a an i ia Ph ht h n n n. ou an S . . a ar t © © 20 c c c rm o o o ur Soc m m m m a . . . c a a a r p i ie ce 02 2 au e 0 t eut 0 M u u . . . D y IV ti ph ica My D D H H al l Be la ha an N HM M M MY Y Y ar V, V N. YL L n L- efi .V - - - V. A 0 0 0 0 0 rm Vi ir i s ra All 01 1 1 1 2 2 2 ma al H s S lr 23 3 3 ri 1 1 1 He Sc ch ig 1- g - - h 0 0 0 00 ac no. 1 P mation before dispensing. Product information is available here or by calling 1800 274 276. P l le ea as se N , Tenofovir Disoproxil Emtricitabine Mylan 300/200 (tenofovir disoproxil maleate 300 mg and emtricitabine 200 mg) , S PBS Information: Authority required (STREAMLINED). Pre-exposure prophylaxis (PrEP) against human immunodeficiency virus (HIV) infection. Treatment of HIV infection. Refer to PBS schedule for full authority information. e r re e v vi ie e w w p p r ro od p pa he ts 0 0 0. a em s re . . E ti me E E it t e ( is s an ese EM M M P PB T T T T- BS r rv - - v 2 2 2 nd S S) e ). ed 0 0 0 .T d 2 2 2 20 Se Te en . A 0 0- - - - e no A 0 0 0 xu ofo lp 00 pha 0 01 1 1 al o a 3 3 3. l H v vi . . . D i p H h ha D D ea r + E ar a a a a r t t lt Em m mP te e e e o h hM mt Pt o o f f Me tr ric ty ed cit yL f p p p d Lt r r r re t e e i c ci tabi d ( p p p pa a i n i (t ar r n tr ra e ( ne e ra a a ad t t ti i i i (A d o o o AS . A i in on SH Av ng n n : : HM ai ga :M M) i l la as M M M ). ab . P ble sM a a ay y y y 2 My Pr 2 2 yl rE e a EP at la 0 0 0 02 2 2 t n n 0 0 0. . . .